Quantcast
Home > Quotes > NEOS

Neos Therapeutics, Inc. Common Stock (NEOS) Quote & Summary Data

NEOS 
$2.03
*  
0.01
0.49%
Get NEOS Alerts
*Delayed - data as of Dec. 13, 2018 15:00 ET  -  Find a broker to begin trading NEOS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    NEOS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.02 / $ 2.03
Today's High / Low
$ 2.105 / $ 2.01
Share Volume
224,137
50 Day Avg. Daily Volume
563,298
Previous Close
$ 2.04
52 Week High / Low
$ 11.69 / $ 1.651
Market Cap
100,842,895
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
224,137
50 Day Avg. Daily Volume:
563,298

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.94

Trading Range

The current last sale of $2.03 is 22.96% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.105 $ 11.69
 Low: $ 2.01 $ 1.651

Company Description (as filed with the SEC)

We are a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing our proprietary modified-release drug delivery technology platform, which we have already used to develop Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER oral suspension ("Adzenys ER"), for the treatment of attention deficit hyperactivity disorder ("ADHD"). Our products are extended-release ("XR"), medications in patient-friendly, orally disintegrating tablets ("ODT") or liquid suspension dosage forms. Our proprietary modified-release drug delivery platform has enabled us to create novel, extended-release ODT and liquid suspension dosage forms. We received approval from the U.S. Food and Drug Administration ("FDA"), for Adzenys XR-ODT, our amphetamine XR-ODT, on January 27, 2016 and launched the commercialization of this product on May 16, 2016.  ... More ...  


Risk Grade

Where does NEOS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.04
Open Date:
Dec. 13, 2018
Close Price:
$ 2.04
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info